MYD88 and metabolic dysfunction-associated steatotic liver disease: In this study, we used HSCs/myofibroblasts-specific MyD88-deficient mice and found that specific deletion of MyD88 in HSCs/myofibroblasts attenuated hepatic steatosis, inflammatory cell infiltration, and adipogenesis in an HFD-induced NAFLD mouse model (Fig. 2).